<DOC>
	<DOCNO>NCT01881334</DOCNO>
	<brief_summary>The objective study make T-cell depleted stem cell family member half match ( haplo-identical ) available expanded access basis patient receive one two unrelated cord blood transplant high risk engraft safe amount time . The purpose related stem cell give bone marrow `` jump start '' towards recovery . Ultimately , cord blood cell grow permanently rescue bone marrow .</brief_summary>
	<brief_title>Expanded Access T-cell Depleted Haplo-Identical Stem Cells Patients Receiving Haplo-Identical Unrelated Cord Blood Transplants</brief_title>
	<detailed_description>The primary purpose study provide expand access T-cell deplete haplo-identical stem cell patient receive allogeneic transplantation relate haplo-identical donor unrelated , umbilical cord blood ( UUCB ) unit ( ) treatment high risk malignancy non-malignant disorder . The T-cell deplete haplo-identical stem cell intend facilitate early , short-term myeloid engraftment primary goal minimize early infection non-relapse mortality UUCB cell engraft durable permanent graft . Patients high risk refractory malignancy , non-malignant disorder amenable stem cell transplantation therapy lack conventional related unrelated donor eligible protocol .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<criteria>Have consent relate haploidentical ( 3/6 , 4/6 , 5/6 DRB1 mismatch ) stem cell donor . Have one two available 4 , 5 , 6/6 antigen matching unrelated UCB unit ( ) deliver total cell dose &gt; 3.0 x 10e7 cells/kg . Patients single UCB unit deliver minimum require cell dose , two partially HLAmatched UCB unit together meet minimum cell dose requirement , use 1 transplant . These unit must HLAmatched minimally 4 6 HLAA B ( intermediate resolution molecular typing ) DRB1 ( high resolution molecular typing ) locus patient , HLAmatched 3 6 HLA A , B , DRB1 locus ( use resolution HLA type indicate ) . There limitation maximum cell dose . Have high risk refractory malignancy , nonmalignant disorder amenable stem cell transplantation therapy . Meet eligibility requirement allogeneic transplant per institutional standard practice . Have give write informed consent accord FDA guideline ( consent parent/legal guardian applicable ) . Be &lt; 65 year age time study enrollment . Have consent 8/8 10/10 allele match , consent , relate unrelated hematopoietic stem cell transplant ( HSCT ) donor . Have life expectancy le 3 month . Have uncontrolled infection time cytoreduction .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Haploidentical Donor</keyword>
	<keyword>T-cell deplete Stem Cells</keyword>
	<keyword>Allogeneic Transplant</keyword>
	<keyword>Umbilical Cord Blood Donor</keyword>
	<keyword>High Risk Malignancies</keyword>
	<keyword>Metabolic Disorders</keyword>
	<keyword>Immune Deficiency</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>CGD</keyword>
	<keyword>SCID</keyword>
	<keyword>Adrenoleukodystrophy</keyword>
	<keyword>Metachromaticleukodystrophy</keyword>
	<keyword>Krabbe</keyword>
	<keyword>PMD</keyword>
	<keyword>Hunter 's</keyword>
	<keyword>Hurler 's</keyword>
	<keyword>Severe Aplastic Anemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Thalassemia</keyword>
</DOC>